Verismo Therapeutics is a developer of CAR-T cell therapy for treatment of cancer. Having spun out of UPenn, Verismo is the only company developing the KIR-CAR platform, a modified NK cell receptor designed to improve persistence and efficacy against aggressive solid tumors. KIR-CAR’s natural on-and-off stimulation to the T cell, as well as the DAP12 costimulatory chains, allows for continued function and persistence.

Verismo has submitted its IND application to the FDA to initiate its Phase 1 clinical trial of SynKIR-110 in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma. Pending regulatory approval, Verismo plans to initiate the STAR-101 trial in Q1 2023.

Contact Verismo Therapeutics
Visit Website